Hologic Announces an Update to Selenia Guidance for Fiscal Third Quarter and Fiscal Year 2006
Increasing Unit Sales of Selenia

BEDFORD, Mass., Jun. 12, 2006 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of state-of-the-art diagnostic and digital imaging systems directed towards women's health, today announced at the Pacific Growth Equities Life Sciences Growth Conference in San Francisco, CA it has updated its previously announced Selenia guidance for fiscal third quarter and fiscal year 2006.

During the presentation, Glenn Muir, Hologic's Executive Vice President and Chief Financial Officer will announce for the fiscal third quarter, the Company expects sales of 130 Selenias (vs. 120 at the April 25, 2006 financial results conference call) and 140 Selenias in the fiscal fourth quarter (vs. 122 projected at the April 25, 2006 financial results conference call). The Company has revised its forecast of Selenia's to reach sales of 478 in the 2006 fiscal year.

"Demand for digital mammography systems continues to grow in the wake of the DMIST results published last September," said Glenn Muir. "In the four-year study of 49,000 women, the accuracy of digital mammography was found to be significantly higher than film-based mammography in an important subset of women which comprised 65% of the study population."

"The growth of our existing mammography segment is gaining momentum as demand for our Selenia full-field digital mammography systems continues to increase," said Jack Cumming, Hologic's Chairman and Chief Executive Officer. "We are winning new customers, as well as additional business from existing customers. We remain committed to meeting the technological design and quality our customers have come to expect from us while at the same time providing value to our shareholders."

About Hologic

Hologic Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. For more information visit

Forward Looking Disclaimer

This news release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the number of Selenia systems that the Company expects to sell in fiscal 2006 and for its fiscal 2006 third and fourth quarters, and expectations regarding the demand for digital mammography systems, including the Company's Selenia system. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, manufacturing risks that may limit the Company's ability to increase commercial production of the Selenia, including the Company's reliance on a single source of supply or manufacturing facility for some key components of its products as well as the need to comply with especially high standards for those components and in the manufacture of digital X-ray products in general; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the ability of the Company's sales force to successfully service its product offerings; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for digital X-ray products; technical innovations that could render products marketed or under development by the Company obsolete; competition; reimbursement policies for the use of the Selenia; the Company's ability to successfully manage recent and pending acquisitions, including the risk that such recent and pending acquisitions will divert management's attention or otherwise result in the Company not operating as effectively and efficiently as expected; the Company's ability to manage current or future alliances or joint ventures; uncertainties relating to litigation, including the FTC's ongoing investigation regarding the Company's acquisition of the mammography intellectual property of Fischer Imaging Systems; and risks relating to compliance with financial covenants under the Company's leases. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

  Contact:  Glenn P. Muir                      Frances Crecco
            Executive Vice President & CFO     Director, Investor Relations
            Hologic, Inc.                      Hologic, Inc.
            (781) 999-7300                     (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir, +1-781-999-7300, or Frances Crecco, +1-781-999-
7377, both of Hologic, Inc.

Web site: